EUKON
Shaping the Future of Interventional Cardiology

Medical technology suppliers are always in pursuit of revolutionary technologies and therapies that can open new avenues in healthcare. A trailblazer among them is EUKON, a biomedical technology company at the forefront of transforming cardiovascular care. It serves as the exclusive distributor of life-saving devices like coronary stents, heart valves, and advanced diagnostic tools.

EUKON acts as a technological talent scout for percutaneous coronary intervention and therapeutic discoveries in Italy’s national healthcare system.

“Building upon our motto of ‘Future Healthcare Now,’ we introduce cutting-edge technologies that help advance the fields of interventional cardiology and beyond,” says Dr. Gennaro Broya de Lucia, founder of EUKON.

Its agility and small structure provide a competitive advantage, allowing it to operate in over 300 public and private healthcare and medical facilities. It collaborates with them to bring forth novel interventional cardiovascular, intensive therapy, and advanced imaging technologies.

Setting EUKON apart is its objective to enter market segments with the most advanced interventions for the non-surgical replacement of heart valves. To achieve this, it has entered long-term agreements with SMT, a leading Indian manufacturer of medical devices, stents, and technologies for cardiovascular patients. Anticipating the future of healthcare with a new coronary stent platform, it is also opening new avenues for advanced plaque identification and follow-up care with its distinctive solutions.

A significant achievement for EUKON is a comprehensive offer of advanced solutions for the private and public healthcare procurement setting trough competitive prices a new access level for best-in-class technologies well accepted in all the scientific community.

By fostering a culture that values compassion, passion, and a positive work environment, it aims to create a tailor-made customer experience for physicians.

Its highly skilled biomedical technologists (the CEO Claudia Mugnoz is a biotechnologist herself) and marketing team actively adopt a human-centric approach, going the extra mile to provide quality products and exceptional customer service.

Embracing a culture of innovation, EUKON started to diffuse high-end, specialized cardiovascular disposable and implantable device product pipeline in 2015. It holds a 10 percent market share of drug-eluting stents (DS) in Italy. Its flagship product, Superflex Cruz, by SMT Sahajanand Medical Technologies, is used in over 300 Italian catheterization laboratories and serves approximately 12,000 patients annually.

EUKON is currently expanding its influence in coronary intervention by venturing into the field of structural heart intervention with the introduction of “Hydra”, a novel aortic valve replacement system, and structural intervention with an AEL-free patent foramen ovale (PFO) closure device called “Cocoon”. Simultaneously, in partnership with Europe, US and Asia based companies, it is developing a diverse portfolio of invasive solutions, such as IVUS combined with infrared endoscopy, micro FFR catheters and “QFR” a digital non-invasive FFR computation backed by AI power from Medis Cardiovascular Imaging.

Building upon our motto of ‘Future Healthcare Now’, we introduce cutting-edge technologies that help advance the fields of interventional cardiology and beyond

In addition to its technological advancements, EUKON, listed 65th on the FT1000 in 2022 by the Financial Times, actively engages in advocacy and industry leadership. Gennaro Broya de Lucia has indeed co-founded and is the current President of the Italian Association of Small and Medium Enterprises in Healthcare, “PMI Sanità”, which plays a vital role in combating the detrimental impact of the medical device payback law. The newly introduced law poses a significant threat to the survival of smaller enterprises. Along with other affected companies, EUKON is actively involved in negotiations with government bodies to repeal this law, safeguarding the Italian healthcare system and SMEs while preserving the lives of countless patients.

Driven to serve the community with a strong team and a resilient spirit, EUKON intends to expand into business segments beyond cardiovascular fields, both in Italy and internationally, while creating value in each specific NHS. Focused on innovation, it is a partner that healthcare systems can rely on to ensure access to the latest innovations in medical technologies. Product manufactures from all over the globe can rely on EUKON as their new doorway to the Italian medical devices marke